Engineering immune cells as dynamic therapies: An evolution-guided framework for temporally programmed CAR T cells

Genetically engineered immune cells have produced durable remissions in several B-cell malignancies, yet relapse, antigen escape, T-cell exhaustion, toxicity, and limited activity in solid tumors remain major barriers. Most current chimeric antigen receptor (CAR) T-cell products operate through a largely fixed functional program after infusion, while emerging strategies often address resistance by increasing potency or constitutively combining multiple functions. Such approaches may be incomplete because both tumor populations and therapeutic immune cells continue to change under treatment. This review evaluates the biological and engineering foundations of engineered immune-cell therapies and develops Adaptive Temporal Immune Programming (ATIP) as an evolution-guided framework for dynamic cell therapy. ATIP reframes CAR T-cell treatment as a control problem involving two evolving populations: the tumor and the therapeutic cells themselves. A single engineered product would contain independently controllable functional modules whose dominance changes sequentially in response to biomarkers or model-predicted escape dynamics rather than a fixed schedule. The framework distinguishes modules that alter tumor-clone selection from those that principally preserve CAR T-cell fitness and requires evidence that candidate modules impose distinct selection pressures before evolutionary steering is inferred. The central hypothesis is that appropriately timed changes in selective pressure could delay resistant-clone dominance while sequential expression reduces the functional burden of simultaneous multi-module activation. ATIP defines explicit assumptions, falsifiable predictions, failure criteria, and a staged experimental program progressing from barcoded mixed-clone cultures through patient-derived organoids and animal models to evolutionary optimal-control modeling. ATIP remains untested and is not evidence of clinical superiority. Its contribution is to shift immune-cell engineering from increasingly complex static therapeutic states toward testing whether living therapies can dynamically alter their functional state in response to the evolution they induce.